Lung Cancer
Conditions
Interventions
Hypofractionated group:Hypofractionated radiotherapy will be given 5 times a week (Monday to Friday) and 4 weeks with a total dose of 60Gy/20Fx/4W at 3 GY/20 fractions by intensity-modulated radiation
Conventional fractionated group:Conventional fractionated radiotherapy will be given 5 times a week (Monday to Friday) and 6 weeks with a total dose of 60Gy/30Fx/6w at 2 GY/30 fractions by intensity-m
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ? NSCLC confirmed by pathological diagnosis; ? Clinical stage III (AJCC/UICCTNM stage 8th) diagnosed by CT, MRI and PET-CT; ?Inoperable: must be consulted by two senior thoracic surgeons in the same center. If the two doctors have different opinions, the third senior thoracic surgeon should be consulted. ? Age =18 years; ? PS 0-1; ? The patients had not received any other anti-tumor treatment before the initial treatment, and had no pleural invasion, pleural effusion, respiratory insufficiency or pathological changes of heart, liver or kidney; ? Negative driver genes mutation in the biopsy samples of adenocarcinoma patients, including EGFR-sensitive mutations (del in exon 19, L858R mutation in exon 21), ALK rearrangement, ROS1 fusion and RET fusion; ? No history of chest radiotherapy; ? Patients who can understand the situation of this study and have signed the informed consent.
Exclusion criteria
Exclusion criteria: ? Patients with other malignant tumors simultaneously or with malignant tumor in other organs and tumor-free survival time 1.5 times the upper limit of normal (ULN); L-Aspartic Acid aminotransferase (AST) and Alanine transaminase (Alt) > 2.5 times the ULN; serum creatinine > 1.5 times the upper limit of normal level and the creatinine clearance rate was less than 60 ml/min; ?Lack of or having limited legal capacity; ?Use of other experimental drugs or participation in other clinical trials; ? Any other condition that the researchers considered unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| time to progression, TTP;objective response rate, ORR;duration of response,DoR;toxicity; | — |
Countries
China
Contacts
Public ContactHe Jian
Zhongshan Hospital, Fudan University
Outcome results
None listed